Latest Dilution News

Legacy Iron Ore Limited reported a quarterly cash flow decline driven by increased mining and exploration expenses but secured $22.5 million in fresh funding to support ongoing operations.

Revolver Resources has locked in A$500,000 through a 1% gross revenue royalty agreement on its Dianne Copper Mine Project, providing crucial non-dilutive funding as it advances toward production.

ReNu Energy has raised $500,000 through loan notes that may convert into shares and options pending shareholder approval, aiming to bolster working capital.

ADX Energy Ltd's December quarter cash flow report reveals a $1.18 million net cash decrease from operations, with $9.08 million cash on hand and ongoing financing adjustments.

Rox Resources has completed its $27 million capital raising with the final tranche of shares issued to institutional investors and company directors, signaling strong backing for its growth plans.

Jervois Global Limited has initiated a prepackaged Chapter 11 recapitalisation process in the US, leading to the suspension of its shares on multiple exchanges. Shareholders are being notified with detailed documentation as the company seeks to restructure its finances.

I Synergy Group Limited has successfully completed a $100,000 private placement at a 16.67% discount, aiming to bolster its growth and working capital. The move signals investor confidence as the technology company advances its digital solutions agenda.

Bio-Gene Technology Limited has been awarded two U.S. Department of Defense grants totaling A$3 million to develop innovative insect control products targeting military and civilian markets.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Waratah Minerals Limited reported a $2.01 million net cash outflow from operating activities in the December 2024 quarter, ending with $4.23 million in cash and equivalents. The company continues its exploration efforts but faces notable cash burn that may pressure future funding.

Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.